Recent Finacing
Recent Raise
Excelimmune develops human recombinant polyclonal antibodies, advancing Staphguard—an HRPA targeting MRSA—from preclinical studies toward IND-enabling development and applying its platform to other pathogens and targets.
Focus Areas
Total Raised
Funding rounds